Department of Hematology and Oncology, The Second Affiliated Hospital of Xi'an JiaoTong University, Xiwu Road 157#, 710004 Xi'an, People's Republic of China.
J Cancer Res Clin Oncol. 2011 Jun;137(6):997-1003. doi: 10.1007/s00432-010-0947-z. Epub 2010 Dec 9.
To explore the effect of low dose of homoharringtonine (HHT) and cytarabine (Ara-c) combined with granulocyte colony-stimulating factor (G-CSF) priming (HAG regimen) on relapsed or refractory acute myeloid leukemia (AML).
Sixty-seven patients with relapsed or refractory acute myeloid leukemia (AML) were enrolled. All the patients were treated with HAG regimen (HHT 1.5 mg/m(2)/day, 1-14d; Ara-C 7.5 mg/m(2)/12 h, 1-14d; G-CSF 150 μg/m(2)/day, according to the counting of the peripheral white blood cells). Blood cell counting, liver, kidney function, ECG and myocardial enzymes were monitored regularly.
Thirty-five of 67 (52.2%) patients achieved complete remission (CR) and 8/67 (11.9%) partial remission (PR). The overall response rate was 64.1%. Myelosuppression was the most frequently observed adverse effect. Sixty of 67 (89.5%) patients suffered from grade 1-4 adverse effects of hematologic toxicity (according to World Health Organization criteria) and non-hematologic toxicity was mild.
In conclusion, HAG regimen was effective and tolerated well in refractory or relapsed AML. As a promising regimen for relapse or refractory AML, further observations should be made.
探讨低剂量高三尖杉酯碱（HHT）联合阿糖胞苷（Ara-c）联合粒细胞集落刺激因子（G-CSF）预处理（HAG 方案）对复发或难治性急性髓细胞白血病（AML）的疗效。
纳入 67 例复发或难治性急性髓细胞白血病（AML）患者。所有患者均采用 HAG 方案（HHT 1.5mg/m(2)/d，1-14d；Ara-c 7.5mg/m(2)/12h，1-14d；G-CSF 150μg/m(2)/d，根据外周血白细胞计数而定）治疗。定期监测血细胞计数、肝肾功能、心电图和心肌酶。
67 例患者中 35 例（52.2%）达到完全缓解（CR），8 例（11.9%）达到部分缓解（PR）。总反应率为 64.1%。骨髓抑制是最常见的不良反应。67 例患者中有 60 例（89.5%）出现 1-4 级血液学毒性（根据世界卫生组织标准）和轻度非血液学毒性。
总之，HAG 方案对难治性或复发性 AML 有效且耐受良好。作为一种有前途的复发或难治性 AML 方案，需要进一步观察。
